Business · Companies · 2 hrs ago
Undecimal Bio launches with $18 million to expand siRNA beyond liver disease
Undecimal Bio has launched with $18 million in funding.
The company aims to use siRNA beyond liver disease.
siRNA is the technology named in the company’s goal, but no further details about its plans are available here.
Undecimal is being carved out of Eleven Therapeutics.
Eleven spun off another part of its business this summer.
The launch and funding mark the next step in separating the two parts of Eleven’s business.
Undecimal Bio has launched with $18 million in funding.
The company aims to expand siRNA beyond liver disease.
The launch follows Eleven Therapeutics spinning out half of its business this summer.
Eleven Therapeutics is now carving out the other half, according to Endpoints News.
- Who
- Undecimal Bio, formed from part of Eleven Therapeutics.
- What
- It launched with $18 million to expand siRNA beyond liver disease.
- When
- October 12, 2026, the article's publication date.
- Where
- Not stated
- Why
- To take siRNA beyond liver disease.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
Eleven Therapeutics spun out half of its business.
Undecimal Bio launched with $18 million to expand siRNA beyond liver disease.
- Funding
- $18 million
- Company
- Undecimal Bio
- Parent company
- Eleven Therapeutics
- Focus
- Expanding siRNA beyond liver disease









